Northern Trust’s Eledon Pharmaceuticals ELDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.68M | Buy |
543,842
+114,029
| +27% | +$269K | ﹤0.01% | 3069 |
|
|
2025
Q4 | $649K | Buy |
429,813
+1,251
| +0.3% | +$2.97K | ﹤0.01% | 3559 |
|
|
2025
Q3 | $1.11M | Sell |
428,562
-25,515
| -6% | -$74.6K | ﹤0.01% | 3355 |
|
|
2025
Q2 | $1.23M | Buy |
454,077
+323,404
| +247% | +$970K | ﹤0.01% | 3272 |
|
|
2025
Q1 | $443K | Buy |
130,673
+3,788
| +3% | +$15.6K | ﹤0.01% | 3625 |
|
|
2024
Q4 | $523K | Buy |
126,885
+34,992
| +38% | +$138K | ﹤0.01% | 3642 |
|
|
2024
Q3 | $229K | Hold |
91,893
| – | – | ﹤0.01% | 3838 |
|
|
2024
Q2 | $243K | Buy |
91,893
+52,089
| +131% | +$124K | ﹤0.01% | 3794 |
|
|
2024
Q1 | $82K | Sell |
39,804
-96
| -0.2% | -$171 | ﹤0.01% | 4130 |
|
|
2023
Q4 | $71.8K | Sell |
39,900
-7,528
| -16% | -$10.5K | ﹤0.01% | 4170 |
|
|
2023
Q3 | $65K | Buy |
47,428
+17,375
| +58% | +$23.2K | ﹤0.01% | 4107 |
|
|
2023
Q2 | $41.2K | Hold |
30,053
| – | – | ﹤0.01% | 4263 |
|
|
2023
Q1 | $70.9K | Hold |
30,053
| – | – | ﹤0.01% | 4172 |
|
|
2022
Q4 | $68.5K | Hold |
30,053
| – | – | ﹤0.01% | 4203 |
|
|
2022
Q3 | $83K | Hold |
30,053
| – | – | ﹤0.01% | 4174 |
|
|
2022
Q2 | $73K | Hold |
30,053
| – | – | ﹤0.01% | 4289 |
|
|
2022
Q1 | $118K | Hold |
30,053
| – | – | ﹤0.01% | 4296 |
|
|
2021
Q4 | $133K | Hold |
30,053
| – | – | ﹤0.01% | 4333 |
|
|
2021
Q3 | $186K | Sell |
30,053
-2,063
| -6% | -$14.4K | ﹤0.01% | 4212 |
|
|
2021
Q2 | $254K | Buy |
32,116
+16,588
| +107% | +$156K | ﹤0.01% | 4047 |
|
|
2021
Q1 | $166K | Buy |
+15,528
| New | +$234K | ﹤0.01% | 4157 |
|
|
2020
Q4 | – | Sell |
-1,294
| Closed | -$22K | – | 4386 |
|
|
2020
Q3 | $22K | Buy |
1,294
+654
| +102% | +$6.44K | ﹤0.01% | 4201 |
|
|
2020
Q2 | $5K | Buy |
+640
| New | +$7.22K | ﹤0.01% | 4233 |
|
|
2017
Q2 | – | Sell |
-649
| Closed | -$87K | – | 4281 |
|
|
2017
Q1 | $87K | Sell |
649
-7
| -1% | -$1.03K | ﹤0.01% | 3985 |
|
|
2016
Q4 | $104K | Buy |
656
+5
| +0.8% | +$958 | ﹤0.01% | 3891 |
|
|
2016
Q3 | $161K | Sell |
651
-139
| -18% | -$50.9K | ﹤0.01% | 3792 |
|
|
2016
Q2 | $705K | Buy |
790
+59
| +8% | +$65.1K | ﹤0.01% | 3433 |
|
|
2016
Q1 | $664K | Sell |
731
-1
| -0.1% | -$982 | ﹤0.01% | 3385 |
|
|
2015
Q4 | $1.03M | Buy |
732
+156
| +27% | +$272K | ﹤0.01% | 3307 |
|
|
2015
Q3 | $966K | Buy |
576
+172
| +43% | +$354K | ﹤0.01% | 3326 |
|
|
2015
Q2 | $871K | Buy |
404
+8
| +2% | +$15.5K | ﹤0.01% | 3394 |
|
|
2015
Q1 | $725K | Buy |
396
+50
| +14% | +$110K | ﹤0.01% | 3502 |
|
|
2014
Q4 | $825K | Buy |
+346
| New | +$821K | ﹤0.01% | 3443 |
|
Other funds holding ELDN
BI
DCM
VCM
ZP
SFM
CCM
BOCH
Northern Trust's ELDN Position: Q1 2026 in Review
Northern Trust increased its Eledon Pharmaceuticals (ELDN) stake by 27% in Q1 2026, buying an estimated $269K and bringing the position to 543,842 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #3069.
Northern Trust first reported a position in ELDN in Q4 2014 and has held it in 33 quarters since. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.
- Northern Trust held 543,842 shares of Eledon Pharmaceuticals worth $1.68M as of Q1 2026.
- Northern Trust bought 114,029 Eledon Pharmaceuticals shares in Q1 2026, an estimated $269K.
- Eledon Pharmaceuticals made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3069 holding.
- Northern Trust first reported a position in Eledon Pharmaceuticals in Q4 2014 and has held it in 33 quarters since.
- 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.
Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.